# Progress Note 07 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Calamity Jane (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI008-SYN-TD
- Date: 1901-06-22
- Fictional facility: St. Posthumous Health Center
- Fictional author: Ruth Ann Kessler, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Sixteen-week review after a two-day return to drinking. **S**

## History of present illness

Ms. Canary returns six weeks after her ten-week review. Her third injection was due four weeks after the second, but she was away for ranch work and it was given four days late. On the two days before it, after a hard week, she drank about half a pint of whiskey each day. On the second day she called the peer recovery specialist, who met her the next morning and brought her to the nurse for the injection. She has had no alcohol in the three weeks since and had no shakes or sweats. She told us about it herself and was afraid we would be angry. Her mammogram at the mobile unit last week was normal. She is eating two or three meals a day. **S**

| Element | Detail |
|---|---|
| Alcohol | Two days of drinking about four weeks ago, about half a pint a day; none in the three weeks since |
| Naltrexone | Third injection four days late; next due in four days |
| Withdrawal | None |
| Mood | PHQ-9 5; GAD-7 5 |
| Mammogram | Normal |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy good; weight rising |
| Gastrointestinal | Negative | No abdominal pain, vomiting or yellowing |
| Neurological | Negative | No tremor or confusion |
| Psychiatric | Positive | Ashamed of the lapse at first, now determined; no thoughts of suicide or self-harm |

4 systems reviewed. **S**

## Current medications

- Thiamine 100 mg oral tablet, one tablet daily **S**
- Folic acid 1 mg oral tablet, one tablet daily **S**
- Extended-release naltrexone 380 mg by deep intramuscular injection into the buttock every four weeks, given by the clinic nurse **S**

## Allergies

- No known allergy **S**

## Objective

BP 116/74 mmHg; pulse 72 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 52.6 kg; BMI 19.3 kg/m². All vital signs are synthetic.

Hemoglobin: 13.1 g/dL; MCV: 95 fL; Platelets: 214 10*3/uL; Sodium: 139 mmol/L; Potassium: 4.2 mmol/L; Creatinine: 0.66 mg/dL; eGFR (CKD-EPI 1896): 111 mL/min/1.73 m²; Glucose: 84 mg/dL; AST: 31 U/L; ALT: 24 U/L; GGT: 58 U/L (high); Albumin: 3.9 g/dL; PEth: 64 ng/mL (high); Liver stiffness (transient elastography): 6.8 kPa; PHQ-9: 5; GAD-7: 5. All results are synthetic.

## Change since baseline

- Hemoglobin: 12.1 g/dL at baseline, 13.1 g/dL at this visit **S**
- MCV: 103 fL (high) at baseline, 95 fL at this visit **S**
- Platelets: 162 10*3/uL at baseline, 214 10*3/uL at this visit **S**
- Sodium: 134 mmol/L (low) at baseline, 139 mmol/L at this visit **S**
- Potassium: 3.3 mmol/L (low) at baseline, 4.2 mmol/L at this visit **S**
- Creatinine: 0.62 mg/dL at baseline, 0.66 mg/dL at this visit **S**
- eGFR (CKD-EPI 1896): 113 mL/min/1.73 m² at baseline, 111 mL/min/1.73 m² at this visit **S**
- Glucose: 78 mg/dL at baseline, 84 mg/dL at this visit **S**
- AST: 96 U/L (high) at baseline, 31 U/L at this visit **S**
- ALT: 44 U/L (high) at baseline, 24 U/L at this visit **S**
- GGT: 240 U/L (high) at baseline, 58 U/L (high) at this visit **S**
- Albumin: 3.4 g/dL (low) at baseline, 3.9 g/dL at this visit **S**
- PEth: 820 ng/mL (high) at baseline, 64 ng/mL (high) at this visit **S**
- PHQ-9: 14 at baseline, 5 at this visit **S**
- GAD-7: 11 at baseline, 5 at this visit **S**

## Immunizations given today

- Hepatitis B vaccine (HepB-CpG), second of two doses **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 116/74, pulse 72; weight 52.6 kg, BMI 19.3 |
| Eyes | No scleral icterus |
| Abdomen | Soft and non-tender; no ascites |
| Neurological | No tremor |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Severe alcohol use disorder in early remission, with a brief return to drinking** (F10.20). Two days of drinking after twelve weeks without alcohol, ended by her own call for help; PEth 64 ng/mL three weeks later agrees with her account. A return to drinking is common in recovery and is not a failure; she used her plan. The late injection may have contributed. Safety reviewed: no thoughts of suicide or self-harm; the rifle remains with her friend. **S**
   - Continue extended-release naltrexone every four weeks; the next injection booked on a day she chose, with a reminder call and a ride if needed.
   - Add a second weekly peer contact for a month.
   - Review her plan for hard weeks with the peer specialist.
2. **Alcohol-associated steatotic liver disease** (K70.0). Liver stiffness 6.8 kPa, below 8 kPa, so advanced fibrosis is unlikely. AST 31 and ALT 24 U/L are normal; GGT 58 U/L remains mildly raised after the lapse; albumin 3.9 g/dL; platelets 214. FIB-4 1.30. **S**
   - Liver tests every six months; elastography yearly while she stays well.
   - Second hepatitis A dose in four months.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Self-management | Drinking since the last visit (her own account, day by day), cravings and triggers | Every visit | Completed today | Two days of drinking about four weeks ago; none since |
| Laboratory | PEth, explained as part of care and not as a test of honesty | At baseline and about every one to two months | Completed today | 64 ng/mL, consistent with her account of two days of drinking |
| Laboratory | Thiamine, folate and electrolytes | Thiamine before glucose and through recovery; electrolytes rechecked within a week if low | Completed today | Thiamine and folic acid continued; hemoglobin 13.1 g/dL, MCV 95 fL; sodium 139, potassium 4.2 mmol/L, creatinine 0.66 mg/dL, eGFR 111, glucose 84 mg/dL |
| Medication safety | Medicine for alcohol use disorder: adherence, side effects, opioid exposure | Every four weeks, on time | Deferred | The third injection was given four days late because she was away for work, and the two days of drinking came just before it. No lasting harm: she stopped within two days, had no withdrawal, and her liver tests and elastography improved. Corrective action: injections are booked on days she chooses, with a reminder call and a ride from the peer specialist |
| Laboratory | Liver enzymes on naltrexone | Baseline, within the first months of treatment, then periodically | Completed today | AST 31, ALT 24 U/L, normal; GGT 58 U/L |
| Imaging | Liver fibrosis: FIB-4, transient elastography, albumin, INR, platelets | Elastography when FIB-4 is above 2.67, repeated after months without alcohol | Completed today | Liver stiffness 6.8 kPa; albumin 3.9 g/dL; platelets 214; FIB-4 1.30 |
| Examination | Weight, meals and food access | Every visit | Completed today | Weight 52.6 kg, BMI 19.3; two or three meals a day |
| Survey | Depression (PHQ-9) and anxiety (GAD-7) after two to four weeks without alcohol | At baseline, after two to four weeks without alcohol, then at least monthly while symptoms persist | Completed today | PHQ-9 5, item 9 scored 0; GAD-7 5; no low mood after the lapse |
| Survey | Suicide-risk review, safety plan, firearm storage and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide or self-harm after the lapse; rifle stored; 988 in her phone |
| Self-management | Peer recovery support and mutual-help meetings | Weekly peer contact; meetings of her choice | Completed today | Weekly calls; the peer specialist met her the morning after the lapse; a second weekly contact added |
| Self-management | Housing, food, income and health coverage | Every visit | Completed today | Still in her room; rent assistance renewed |
| Self-management | Chewing tobacco | Every visit | Completed today | Cutting down; would like to try nicotine lozenges next month |
| Medication safety | Naloxone | Reassess at every visit | Not indicated | No opioid use |

## Goal progress

- Finish withdrawal safely at home without a seizure or delirium. Outcome by 1901-03-09: Five days of gabapentin with daily nurse checks; CIWA-Ar 9 at intake, 10 at most, 2 at one week; no seizure, hallucinations or confusion. **S**
- No drinking, her goal, with a medicine for alcohol use disorder. Outcome by 1901-06-22: No alcohol for twelve weeks, then two days of drinking in late May, followed by three weeks without; PEth 820 to 24, then 64 after the lapse. **S**
- Liver tests back to normal and a clear answer on liver scarring. Outcome by 1901-06-22: AST 96 to 31 and ALT 44 to 24 U/L; liver stiffness 9.6 to 6.8 kPa; no advanced fibrosis. **S**
- Regular meals and a healthier weight. Outcome by 1901-06-22: Weight 50.0 to 52.6 kg (BMI 18.4 to 19.3); SNAP benefits and two meals a day on most days. **S**
- A room of her own and health coverage. Outcome by 1901-06-22: Medicaid approved by the four-week visit; a rented room through a housing program by the ten-week visit. **S**
- PHQ-9 below 10, and reassessment once she has stopped drinking. Outcome by 1901-05-11: PHQ-9 14 to 5 after ten weeks without alcohol. **S**

## Guideline basis

- The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder (2018), American Psychiatric Association (American Journal of Psychiatry 2018;175(1):86-90)
- The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management (2020), American Society of Addiction Medicine (Journal of Addiction Medicine 2020;14(3S Suppl 1):1-72)
- The Healthcare Professional's Core Resource on Alcohol (2026), National Institute on Alcohol Abuse and Alcoholism
- Diagnosis and Treatment of Alcohol-Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases (2019), American Association for the Study of Liver Diseases (Hepatology 2020;71(1):306-333)
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense
- CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026), Aether Forge

## Follow-up

- Second hepatitis B dose given today. Naltrexone injection in four days at a nurse visit. Review in two months. Second hepatitis A dose in four months. Call the peer specialist, the clinic or 988 at any time. **S**

